H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Tyra Biosciences (TYRA) to $30 from $32 and keeps a Buy rating on the shares. The firm says TYRA-300 data in non-muscle-invasive bladder cancer is track for the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience
- Tyra Biosciences reports Q3 EPS (41c), consensus (40c)
- 3 Best Stocks to Buy Now, 10/28/2024, According to Top Analysts
- Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300
- Tyra Biosciences price target raised to $32 from $30 at H.C. Wainwright